Development of acute kidney injury following repair of Stanford type A aortic dissection is associated with increased mortality and complications: a systematic review, metaanalysis, and meta-regression analysis

Aman Goyal^a, Surabhi Maheshwari^b, Haleema Qayyum Abbasi^c, Yusra Mashkoor^d, Urooj Shamim^e, Mahla Chambari^f, Arjun Kelaiya^g, Darsh Safi^a, Humza Saeed^h, Hritvik Jainⁱ, Prakriti Pokhrel^j and Irfan Ullah^k

Acute kidney injury (AKI) frequently complicates the repair of Stanford type A aortic dissection (TAAD). This systematic review, meta-analysis, and meta-regression analysis aimed to elucidate the prognostic impact of AKI in these patients. A literature search in PubMed, EMBASE, and Google Scholar identified relevant studies on the predictors and outcomes of AKI following TAAD repair. The primary endpoint was 30-day mortality; secondary endpoints included stroke, dialysis/continuous renal replacement therapy (CRRT), and other complications. Random-effects meta-analyses were used, with significance set at P < 0.05. Twenty-one studies (10 396 patients) were analyzed. AKI was associated with higher risks of 30-day mortality (risk ratio = 3.98), stroke (risk ratio = 2.05), dialysis/CRRT (risk ratio = 32.91), cardiovascular (risk ratio = 2.85) and respiratory complications (risk ratio = 2.13), sepsis (risk ratio = 4.92), and re-exploration for bleeding (risk ratio = 2.46). No significant differences were noted in sternal wound infection, tracheostomy, paraplegia, or hepatic failure. AKI significantly increases mortality, morbidity, hospital,

Introduction

Type A aortic dissection (TAAD) is defined as separation of the aortic wall involving the ascending aorta, irrespective of the site of the intimal tear (Stanford Classification) [1]. Acute TAAD is a common cardiac emergency, and despite advances in diagnostic modalities, intraoperative techniques, and perioperative care, TAAD repair is associated with approximately 12% in-hospital mortality [2,3]. Postoperative acute kidney injury (AKI) after repair of TAAD is an early and common complication with an incidence ranging from 20.2 to 66.7%. It ranges from mild renal dysfunction to renal failure, requiring renal replacement therapy (RRT) [4–6]. It is associated with

and ICU stay duration in TAAD repair patients. *Cardiovasc Endocrinol Metab* 13: 1–15 Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Cardiovascular Endocrinology & Metabolism 2024, 13:1-15

Keywords: acute kidney injury, aortic dissection, cardiology, meta-analysis, mortality, prevention

Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India, ¹Department of Internal Medicine, University of Alabama, Montgomery, Alabama, USA, ¹Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan, ¹Department of Internal Medicine, Dow University of Health Sciences, ¹Department of Critical Care Medicine, Mayo Clinic Jacksonville, Jacksonville, Florida, USA, ¹Department of Food Science and Nutrition, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia, ¹Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan, ¹Department of Internal Medicine, All India Institute of Medical Sciences-Jodhpur, Jodhpur, Rajasthan, India, ¹Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal, and ¹Department of Internal Medicine, Khyber Teaching Hospital, Peshawar, Pakistan

Correspondence to Prakriti Pokhrel, MBBS, Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, 33700 Kathmandu, Nepal E-mail: prakriti.pokhrel@kmc.edu.np

Received 1 July 2024 Accepted 1 October 2024.

adverse outcomes such as increased in-hospital morbidity and mortality, longer hospital stay, and reduced long-term survival [7–9]. The causative mechanisms of postoperative AKI are not always evident and are multifactorial. There is no known pharmacological treatment to prevent or treat AKI, and many patients require continuous renal replacement therapy (CRRT), which is associated with increased mortality [10,11]. Although several studies have explored the prognostic significance of postoperative AKI, there remains a lack of sufficient investigation into its impact on the occurrence of 30-day postoperative mortality and morbidities, including cardiovascular, respiratory, and other complications. Some studies have found only severe AKI is associated with increased 30-day postoperative mortality, whereas others have demonstrated that AKI, regardless of severity, increases mortality [4,11–13].

Recently, several systematic reviews and meta-analyses have attempted to establish the relative significance of

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.cardiovascularendocrinology.com.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

risk factors and adverse outcomes [12–14]. Kidney disease was defined in several ways, including the Kidney Disease: Improving Global Outcomes (KDIGO) definition and staging system, the Risk, Injury, Failure, Loss of kidney function (RIFLE) criteria, and the Acute Kidney Injury Network (AKIN) classification [15–17]. Owing to the inter-definition variability and evaluation of different outcomes in each study, there are inconsistencies in establishing the relative significance of AKI on prognosis after repair of TAAD. Thus, our systematic review and meta-analysis aimed to understand the prognostic significance of the development of AKI in patients who have undergone repair of TAAD, by understanding its effects on the risk of mortality and several other outcomes.

Materials and methodology

We adhered to the guidelines established by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) for our systematic review and meta-analysis [18]. We registered our protocol in the International PROSPERO Registry for Systematic Reviews and Meta-Analyses (CRD42023486286). Our study has been reported in line with the AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines [19].

Data sources and search strategy

Two authors independently conducted an extensive literature search to identify relevant studies on the predictors and outcomes of AKI following TAAD repair.

The authors meticulously searched for relevant articles using various databases, including PubMed, Google Scholar, EMBASE, Scopus, and the Cochrane Library. To ensure the comprehensiveness of the review, references from retrieved studies, prior meta-analyses, and review articles were examined. Additionally, they meticulously scanned citations on Google Scholar to identify any pertinent literature. In instances where deemed appropriate, attempts were made to contact the authors via email to request additional data; however, no responses were received.

The search strategy employed a string of keywords and related Medical Subject Headings terms, encompassing 'Acute Kidney Injury', 'AKI', 'Type A Aortic Dissection', 'Predictors', and 'Outcomes'.

Eligibility criteria

Utilizing the Population, Exposure, Control, and Outcomes (PECO) framework for systematic reviews and meta-analyses, we assessed the inclusion criteria. In our study, 'P' represented patients who had undergone repair for TAAD, 'E' referred to patients who developed AKI, 'C' denoted patients who did not develop AKI, and 'O' encompassed various outcomes as subsequently discussed. The exclusion criteria included non-adult populations, interventions other than repair, and studies lacking relevant AKI outcome data. Additionally, case reports, review articles, and abstracts without full text were excluded from the analysis.

Endpoints

This study aimed to evaluate the 30-day mortality rate (primary endpoint) and various secondary endpoints, including stroke incidence, need for dialysis/CRRT, cardiovascular and respiratory complications, sepsis, re-exploration for bleeding, sternal wound infection, tracheostomy requirement, paraplegia, hepatic failure, and length of hospital and ICU stay.

Study selection and data extraction

After retrieving all relevant studies through a thorough literature search, they were imported into EndNote X9 (Clarivate Analytics) for removal of duplicates. Two authors independently reviewed the abstracts and those meeting the eligibility criteria were included after a fulltext assessment. Disagreements were resolved through discussion and consensus between the two authors. A pre-piloted Microsoft Excel sheet was used to facilitate data extraction.

Quality assessment of included studies

The current meta-analysis included observational studies, and the quality of the included studies was evaluated using the Newcastle–Ottawa Scale. This was accomplished by two researchers whose findings were compared to eliminate inconsistencies. The Newcastle– Ottawa scale focuses on the selection criteria of studies, comparability between groups, exposure, and outcomes [20].

Data synthesis

Data synthesis for this meta-analysis was performed using RevMan version 5.4, developed by the Nordic Cochrane Center in Copenhagen, Denmark. Pooled analysis of studies was represented in the form of forest plots, with statistical significance set at P < 0.05, within a 95% confidence interval (CI). All analyses were performed using the Mantel–Haenszel random-effects model. The effect measure was the risk ratio for dichotomous variables and mean difference for continuous variables.

To evaluate the degree of heterogeneity arising from differences in methodologies, study designs, and populations, the Higgins I^2 metric was used [21]. A value of less than 50% indicated low heterogeneity, exceeding 50% indicated moderate heterogeneity, and a value greater than 75% indicated significant heterogeneity. To gauge the robustness of the findings, sensitivity analysis was performed by systematically excluding one study at a time. Meta-regression analysis was performed to explore various covariates (baseline mean age, baseline BMI,



Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram (2020) for systematic reviews and meta-analyses.

baseline kidney function, and gender) that may have led to potential heterogeneity among the studies. To assess publication bias, a visual analysis of the funnel plots was conducted.

Results

Literature search results

Using the predefined search strategy, 1147 references were identified through four electronic database searches. After removing 298 duplicates, 849 articles were screened based on their titles and abstracts, resulting in the further exclusion of 788 articles. The remaining 61 articles underwent full-text review, leading to the exclusion of

40 studies due to irrelevant populations, lack of relevant outcomes, irrelevant study design, and unavailability of full text or full text not in the English language. Consequently, 21 studies that met the eligibility criteria were included in our meta-analysis [4,6,14,20,22–38]. A comprehensive overview of the literature search and study selection process is shown in Fig. 1.

Study characteristics and risk of bias assessment

Of the included studies, 19 were retrospective [4,6,22,23,25–27,29–33,35,37–42], while two followed a prospective design [24,28]. Fifteen studies originated in China [6,22,23,26–33,35,38–40], two each from Japan

[4,37] and the USA [24,25], and one each from Italy [42] and Iceland [41]. The collective cohort comprised 10 396 patients undergoing aortic arch repair, with 3928 in the AKI group and 6468 in the non-AKI group, respectively. The mean ages across the studies ranged from 33 to 68 years, with the proportion of male participants varying from 39.9% to 100%. Additionally, 15 of the included studies used the KDIGO criteria to diagnose AKI. The most common comorbidities reported were diabetes and hypertension. The baseline characteristics of all studies are summarized in Table 1.

All studies underwent high-quality assessment, scoring eight or higher on the Newcastle-Ottawa Scale (Table 2). Funnel plots for nearly all outcomes were symmetrical, demonstrating a minimal publication bias (Supplementary Fig. 1, Supplemental digital content 1, http://links.lww.com/CAEN/A61).

Endpoints

This study showed that 37.8% of patients undergoing TAAD repair develop AKI, highlighting its potential impact on patient outcomes.

Primary endpoint of 30-day mortality

Eighteen of the 21 included studies reported data on 30-day mortality [4,22–25,27–33,37–42]. Patients with AKI exhibited a significantly higher risk of 30-day mortality as compared to those without AKI (risk ratio = 3.98, 95% CI: 3.04–5.22, P < 0.001), with 57% heterogeneity detected across studies ($I^2 = 57\%$, P for heterogeneity = 0.001) (Fig. 2). The sensitivity analysis showed that 'Wang-1 *et al.* (2020)' [22] might be the source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 44\%$).

Secondary endpoints

Stroke

Eleven of the 21 included studies reported data on stroke [4,6,22,24,25,27,37,39–42]. Patients with AKI had a significantly higher risk of experiencing stroke than those without AKI (risk ratio = 2.05, 95% CI: 1.68–2.50, P < 0.001), with 32% heterogeneity detected across studies ($I^2 = 32\%$, P for heterogeneity = 0.14) (Fig. 3a).

Need for dialysis/continuous renal replacement therapy

Fifteen of the 21 included studies reported data on patients who required dialysis or CRRT [4,6,22–25,29,32,33,37– 42]. A significantly increased risk of dialysis/CRRT was observed in the AKI group compared to that in the non-AKI group (risk ratio = 32.91, 95% CI: 10.39–104.24, P < 0.001), with 90% heterogeneity detected across studies ($I^2 = 90\%$, P for heterogeneity < 0.001) (Fig. 3b). Upon performing sensitivity analysis, no significant reduction in heterogeneity was observed.

Cardiovascular complications

Of the 21 included studies, 10 reported data on postoperative cardiovascular complications [4,22,25,27,31– 33,37,39,41]. Patients with AKI had a significantly higher risk of cardiovascular complications than those in the non-AKI group (risk ratio = 2.85, 95% CI: 1.65–4.92, P < 0.001), with 85% heterogeneity detected across studies ($I^2 = 85\%$, P for heterogeneity < 0.001) (Fig. 4a). Sensitivity analysis showed 'Helgason *et al.* (2021)' [41] might be the source of heterogeneity. After excluding this study, no heterogeneity was observed ($I^2 = 0\%$, P for heterogeneity > 0.1).

Respiratory complications

Eight of the 21 included studies reported data on postoperative respiratory complications (pneumonia and respiratory failure) [23,30–32,38,39,41,42]. Patients with AKI demonstrated a significantly higher risk of respiratory complications than those without AKI (risk ratio = 2.13, 95% CI: 1.16–3.91, P = 0.02), with 82% heterogeneity detected across studies ($I^2 = 82\%$, P for heterogeneity < 0.001) (Fig. 4b). A sensitivity analysis showed that 'Li *et al.* (2020)' [38] might be a source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 58\%$, P for heterogeneity > 0.1).

Sepsis

Five of the 21 included studies reported sepsis data [24,29,37,39,41]. A significantly higher risk of sepsis was observed in the AKI group than in the non-AKI group (risk ratio = 4.92, 95% CI: 2.62–9.24, P < 0.001), with 64% heterogeneity detected across studies ($I^2 = 64\%$, P for heterogeneity = 0.03) (Fig. 4c). Sensitivity analysis showed 'Helgason *et al.* (2021)' [41] might be the source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 14\%$, P for heterogeneity > 0.1).

Reexploration for bleeding

Twelve of the 21 included studies reported data for reexploration for bleeding [4,22–25,27,29,30,33,40–42]. Patients with AKI had a significantly higher risk of undergoing re-exploration for bleeding than those without AKI (risk ratio = 2.46, 95% CI: 1.79–3.39, P < 0.001), with 58% heterogeneity detected across studies ($I^2 = 58\%$, P for heterogeneity = 0.007) (Fig. 5a). The sensitivity analysis showed that 'Wang-2 *et al.* (2020)' [23] might be the source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 42\%$, P for heterogeneity > 0.1).

Sternal wound infection

Four of the 21 included studies reported data on sternal wound infection [22,23,40,41]. A nonsignificant increase in the risk of sternal wound infection was noted in the AKI group compared to the non-AKI group (risk ratio = 1.19,

included studies
among the
of patients
characteristics
Baseline
Table 1

Marfan syndrome (8/7.1) Cerebrovascular disease (4.5/7.1) (Continued)										
DM (4.5/2.4) HTN (76.1/76.2)	70.5/73.8	28.1/25	48.8/47.9	88 (51.2)	KDIGO	Acute TAAD	88/84	172	Betrospective, Single center	Chinia/ الحك Guan <i>et al.</i> (2023, China) [29]
Cardiac tamponade (14/13) NR	76.6/78.5	25.9/26.6	49/46.1	228 (54.2)	KDIGO	Acute TAAD	193/228	421	Retrospective, Single center	Li <i>et al.</i> (2021, China) [26]
Previous (29/24) PAD (0.6/1.4) Previous cardiac surgery (7/5) Previous coronary disease (9/4) Certebrovascular disease (9/9)										
Previous coronary disease (3.5/2.9) CKD (1.6/1.6) DM (5/8) HTN (81/81)	60/46	24/22.6	65.5/67	165 (44)	KDIGO	Acute TAAD	165/210	375	Retrospective, Sincle center	Ko <i>et al.</i> (2015, Ianan) [37]
Previous coronary disease (17.7/13.8) Aortic valve insufficiency (49.4/40.7) Cardiac tamponade (30/37.7) DM (2.5/2.6) HTN (63.4/56.6)	82.8/78.5	۲ ۲	54.2/51.4	314 (50.6)	KDIGO	TAAD	314/307	621	Prospective, Single center	Fang <i>et al.</i> (2023, China) [28]
Previous coronary disease (20.9/13.1) Cerebrovascular disease (9.2/7) Cardiac tamponade (11.8/9.2) DM (14.1/9.9) HTN (77.7/75.8) COPD (17.7/13.8) PAD (42.4/33.1)	40/39.9	30.1/30	62/61.3	85 (14.1)	RIFLE	Acute TAAD	85/516	601	Prospective, Single center	Brown <i>et al.</i> (2022, USA) [24]
CCD (16, 4000, 100	68.6/75.1	25.8/25.9	50.6/48.9/	153 (40.1)	KDIGO	TAAD	153/229	382	Retrospective, Single center	Chen <i>et al.</i> (2023, China) [27]
DM (15.7/11.2) HTN (84.1/74.6) Smoking (31.3/28.9) COPD (9.8/79) PAD (5.1/2.7) Previous cardiac surgery (4.4/6.1) Previous coronary disease (3.9/3.6)	71.2/64.3	28.6/27.6	61.4/60.2	761 (23)	RIFLE	Acute TAAD	761/2546	3307	Retrospective, Single center	Arnaoutakis <i>et al.</i> (2023, USA) [25]
Comorbidities, % (AKI/non-AKI)	Male, % (AKI/non- AKI)	Mean BMI, kg/ m² (AKI/ non-AKI)	Mean age, years (AKI/ non-AKI)	AKI incidence, <i>n</i> (%)	Diagnostic criteria of AKI	Diagnosis of patients	Sample size, <i>n</i> (AKI/Non-AKI)	Total no. of participants, <i>n</i>	Study type	Author (year, country)

Author (year, country)	Study type	Total no. of participants, <i>n</i>	Sample size, <i>n</i> (AKI/Non-AKI)	Diagnosis of patients	Diagnostic criteria of AKI	AKI incidence, <i>n</i> (%)	Mean age, years (AKI/ non-AKI)	Mean BMI, kg/ m² (AKI/ non-AKI)	Male, % (AKI/non- AKI)	Comorbidities, % (AKI/non-AKI)
Li e <i>t al.</i> (2020, China) [38]	Retrospective, Single center	335	241/94	TAAD	KDIGO	241 (71.94)	47.9/46.6	25.3/23.5	83.4/73.4	DM (2.9/3.1) HTN (57.6/44.6) Hyperlipidemia (7.8/1.1) COPD (6.2/2.1) Previous cardiac surgery (3.3/9.5) Previous coronary disease (31.9/25.5)
Liu T <i>et al.</i> (2021, China) [30]	Retrospective, Single center	1 5	61/54	Acute DeBakey Type I AD	KDIGO	61 (53)	48.7/46.8	27.2/25	72.1/77.8	CKD (8.1.1.1) Marfan syndrome (3.3.9.1) DM (9.8/1.9) HTN (82/77.8) Smoking (55.7/40.7) Alcohol consumption (19.7/20.4) Previous contonav disease (4.9/5.6)
Wang-1 <i>et al.</i> (2020, China) [22]	Retrospective, Single center	214	114/100	Acute TAAD	KDIGO	114 (53.3)	68/66	24.2/24.2	56.1/59	Cerebrovascular disease (3.3/7.4) DM (2.6/1) HTN (73.7/74) Previous cardiac surgery (7.9/5) Previous contary disease (6.1/8) Condensional disease (6.1/8)
Wang-2 <i>et al.</i> (2020, China) [23]	Retrospective, Single center	712	359/353	Acute TAAD	KDIGO	359 (40.4)	53.7/51.3	25.9/24.7	73.3/73.4	Ceretorovascula clasass (0.175) Pericardial effusion (4.4/4) DM (1.9/1.4) HTN (74.7/63.5) Previous cardiac surgery (5.8/4.2) Previous coronary disease (3.9/3.7)
Zhang <i>et al.</i> (2022, China) [35]	Retrospective, Single center	224	53/171	Acute TAAD	KDIGO	(23.66)	55.2/51.8	26.6/26.7	71.7/78.4	Cerebrovascular clasase (3.6/3.1) Pericardial effusion (2.5/5.4) DM (0/2.9) HTN (79.2/67.3) Smoking (54.7/46.2) Alcohol consumption (24.5/228)
Sasabuchi <i>et al.</i> (2016, Japan) [4]	Retrospective, Single center	403	181/222	Acute TAAD	KDIGO	181 (44.9)	63/66	х Х	59.7/44.6	Previous cardiac surgery (1.9/2.3) Cerebrovascular disease (7,5/6.4) DM (7,7/5.9) HTN (75.7/68) Hyperlipidemia (16.6/14) Smoking (40.3/29.7) CODP (1.7/3.2) PAD (1.7/0.5)
Qiu <i>et al.</i> (2015, China) [32]	Retrospective, Single center	155	56/99	Acute TAAD	AKIN	56 (36.13)	56.1/56.1	N	82.1/71	Previous cardiac surgery (0.6/1.8) Previous cardiac surgery (0.6/1.8) Marfan syndrome (1.7/3.6) Bicuspid aortic valve (1.1/0.9) Cerebrovascular disease (9.9/7.7) DM (8.9/8) HTN (78.5/67)

(Continued)

(year, untry)	Study type	Total no. of participants, <i>n</i>	Sample size, <i>n</i> (AKI/Non-AKI)	Diagnosis of patients	Diagnostic criteria of AKI	AKI incidence, <i>n</i> (%)	Mean age, years (AKI/ non-AKI)	BMI, kg/ m² (AKI/ non-AKI)	Male, % (AKI/non- AKI)	Comorbidities, % (AKI/non-AKI)
t <i>al.</i> aly)	Prospective, Single center	37	14/23	Acute TAAD	RN	(37.8)	65/65	NR	92.8/78.2	Cardiac tamponade (50/60.8)
.023, 33]	Retrospective, Single center	624	235/389	Acute TAAD	KDIGO	235 (37.7)	50.9/47	26/26.1	67.7/77.4	DM (5.5/2.1) HTN (59.6/49.1) Smoking (33.6/33.4) COPD (0.9/0.3) Previous cardiac surgery (2.1/1.5) Previous coronary disease (7.2/5.9)
(2022, 39]	Retrospective, Single center	8 6 8	268/130	TAAD	KDIGO	268 (67.3)	49/47.2	25.8/24.3	82.1/75.4	Cereprovascular disease (172.3) DM (1.9/0) HTN (78.170) COPD (0.7/2.3) Previous condray disease (1.9/1.5) Previous condrary disease (1.9/1.5)
. (2015, 6]	Retrospective, Single center	108	72/36	Acute TAAD	AKIN	72 (66.7)	44/43	29.6/29.7	94.4/100	Martan Syndrome (1.1.03.1) DM (2.8/5.6) HTN (80.6/83.3) Smoking (81.9/278) COPD (1.4/0) Previous cardiac surgery (51.4/33.3)
. (2020, 40]	Retrospective, Single center	121	51/p70	Acute TAAD	KDIGO	51 (42.1)	35/33	26.3/24.7	78.4/84.3	Previous coronary disease (6.9/5.6) Cerebrovascular disease (1.4/0) DM (2/0) HTN (70.6/35.7) Previous cardiac surgery (5.9/4.3) Previous coronary disease (5.9/0)
. (2020, 31]	Retrospective, Single center	130	82/48	Acute TAAD	KDIGO	82 (63.08)	54.7/53.1	NR	80.3/68.7	Cerebrovascular disease (z/u) Pericardial effusion (0/1.4) DM (7.8/2.1) HTN (66.6/45.8) COPD (5.8/4.1) Previous coronary disease (3.9/2.1)
et al. 11]	Retrospective, multicenter	941	382/5559/941	Acute TAAD	RIFLE	382(40.6)	63.1/60.3	27.6/ 26.1	70.2/64.9	Cerebrovascular disease (5.8/6.2) DM (2.6/1.8) HTN (6.8.6/47.8) CAD (5.3.2.9) Smoking (35.1/34.5) Cerebrovascular disease (5.3/2.9) Bicuspid valve (6.1/6.3)

Table 1 (Continued)

Table 2 Risk of bias sum	mary of included	observational	studies using N	ewcastle-Ottawa Scale					
	Representative	Selection of		Demonstration that outcome	Comparability of		Was follow-up long	Adequacy of	
	of exposed	nonexposed	Ascertainment	of interest was not present at	cohort on the basis of	Assessment	enough for the	follow-up of	Total
Study	cohorts	cohort	of exposure	the start of study	design or analysis	of outcome	outcomes to occur	cohorts	score
Li 2021 <i>et al.</i> [26]	*	*	*	*	*	*	*	*	ω
Arnaoutakis <i>et al.</i> [25]	*	*	*	*	*	*	*	*	8
Brown <i>et al.</i> [24]	*	*	*	*	**	*	*	*	6
Chen <i>et al.</i> [27]	*	*	*	*	**	*	*	*	6
Fang <i>et al.</i> [28]	*	*	*	*	*	*	*	*	8
Guan <i>et al.</i> [29]	*	*	*	*	*	*	*	*	8
Helgason <i>et al.</i> [41]	*	*	*	*	*	*	*	*	80
Ko <i>et al.</i> [37]	*	*	*	*	*	*	*	*	80
Li 2020 <i>et al.</i> [38]	*	*	*	*	*	*	*	*	80
Liu 2020 <i>et al.</i> [31]	*	*	*	*	**	*	*	*	б
Liu 2021 Y <i>et al.</i> [30]	*	*	*	*	**	*	*	*	б
Qiu <i>et al.</i> [32]	*	*	*	*	*	*	*	*	80
Sansone et al. [42]	*	*	*	*	**	*	*		80
Sasabuci <i>et al.</i> [4]	*	*	*	*	*	*	*	*	80
Wang Aug <i>et al.</i> [22]	*	*	*	*	**	*	*	*	о
Wang July <i>et al.</i> [23]	*	*	*	*	*	*	*	*	80
Xu et al. [33]	*	*	*	*	*	*	*	*	80
Yang <i>et al.</i> [39]	*	*	*	*	**	*	*	*	6
Zhang <i>et al.</i> [35]	*	*	*	*	**	*	*	*	6
Zhao <i>et al.</i> [6]	*	*	*	*	**	*	*	*	о
Zong <i>et al.</i> [40]	*	*	*	*	**	*	*	*	6

Need for tracheostomy

*Score > 7 was considered as a good quality study with low risk of bias

Five of the 21 included studies reported data on the need for a tracheostomy [22,23,37,40,41]. Patients with AKI exhibited a nonsignificantly increased risk of tracheostomy compared to those without AKI (risk ratio = 2.10, 95% CI: 0.72–6.15, P = 0.18), with 85% heterogeneity detected across studies ($I^2 = 85\%$, P for heterogeneity < 0.001) (Fig. 5c). Sensitivity analysis showed 'Helgason et al. (2021)' [41] might be the source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 27\%$, P for heterogeneity > 0.1).

Paraplegia

Three of the 21 included studies reported data on paraplegia [22,23,40]. A nonsignificantly increased risk of paraplegia was observed in the AKI group compared to the non-AKI group (risk ratio = 0.73, 95% CI: 0.36-1.46, P = 0.37), with no heterogeneity detected across studies $(I^2 = 0\%, P \text{ for heterogeneity} = 0.62)$ (Fig. 6a).

Hepatic failure

Two of the 21 included studies reported data on hepatic failure [38,39]. Patients with AKI had a nonsignificantly increased risk of hepatic failure compared to the non-AKI group (risk ratio = 1.45, 95% CI: 0.18–11.55, P = 0.73), with 92% heterogeneity detected across studies ($I^2 = 92\%$, *P* for heterogeneity < 0.001) (Fig. 6b). Upon performing sensitivity analysis, no significant reduction in heterogeneity was observed.

Length of stay

Seven [23,24,29,35,38,40,42] of the 21 included studies reported data for length of hospital stay, with 74% heterogeneity detected across studies ($I^2 = 74\%$, P for heterogeneity < 0.001) (Fig. 6c). The sensitivity analysis showed that 'Brown et al. (2022)' [24] might be a source of heterogeneity. After excluding this study, the heterogeneity between the studies was reduced ($I^2 = 51\%$, *P* for heterogeneity > 0.1). Four of the 21 included studies reported data on the length of stay in the ICU [23,28,40,42]. Patients with AKI had a significantly longer duration of ICU stay than those without AKI (mean difference = 4.01, 95% CI: 1.83–6.20, P < 0.001), with 79% heterogeneity detected across studies ($I^2 = 79\%$, P for heterogeneity < 0.001) (Fig. 6d). Upon performing sensitivity analysis, no significant reduction in heterogeneity was observed.

Meta regression analysis

We performed a meta-regression analysis for numerous covariates, namely mean age of patients in the study, mean baseline BMI of patients, gender, and baseline

	AK		Non-A	KI		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Arnaoutakis 2023	193	761	122	2546	12.7%	5.29 [4.28, 6.54]	+
Brown 2022	29	85	38	516	10.3%	4.63 [3.03, 7.09]	
Chen 2023	13	153	6	229	5.1%	3.24 [1.26, 8.35]	
Fang 2023	42	314	5	307	5.4%	8.21 [3.29, 20.48]	
Guan 2023	16	88	2	84	2.8%	7.64 [1.81, 32.21]	
Helgason 2021	65	382	37	559	10.8%	2.57 [1.75, 3.77]	
Ko 2015	6	165	0	210	0.8%	16.52 [0.94, 291.22]	· · · · · · · · · · · · · · · · · · ·
Li 2020	51	241	9	94	7.5%	2.21 [1.13, 4.31]	
Liu 2021	8	61	1	54	1.6%	7.08 [0.92, 54.81]	
Liu Y 2020	19	82	2	48	2.9%	5.56 [1.35, 22.84]	
Qiu 2015	6	56	1	99	1.5%	10.61 [1.31, 85.89]	· · · · · · · · · · · · · · · · · · ·
Sansone 2015	7	14	3	23	3.8%	3.83 [1.18, 12.45]	
Sasabuci 2016	15	181	4	222	4.3%	4.60 [1.55, 13.62]	
Wang-1 2020	30	114	16	100	8.8%	1.64 [0.95, 2.83]	
Wang-2 2020	65	359	25	353	10.1%	2.56 [1.65, 3.96]	
Xu 2023	46	235	14	389	8.5%	5.44 [3.06, 9.67]	
Yang 2022	46	268	1	130	1.7%	22.31 [3.11, 160.01]	│
Zong 2020	6	51	1	70	1.5%	8.24 [1.02, 66.32]	
Total (95% CI)		3610		6033	100.0%	3.98 [3.04, 5.22]	•
Total events	663		287				
Heterogeneity: Tau ² =	0.14; Ch	i ^z = 39.	87, df = 1	7 (P = 0	0.001); I ^z :	= 57%	
Test for overall effect:	Z = 10.00) (P < 0	.00001)				Favours [AKI] Favours [Non-AKI]

Forest plot for the outcome of 30-day mortality.

kidney function, against the outcomes of 30-day mortality, stroke, and need for dialysis/CRRT. Our analysis found no significant correlation between the outcomes and covariates.

Discussion

This meta-analysis revealed a combined incidence of 37.8% for postoperative AKI after TAAD repair, supporting a previously reported range of 18–87% [34,36,43]. Our findings demonstrate that patients experiencing AKI face a significantly elevated risk of adverse events, including mortality, stroke, the need for dialysis, cardiovascular and respiratory complications, sepsis, re-exploration for bleeding, prolonged hospital stay, and an extended ICU stay. These results underscore the severity of AKI and highlight the importance of promptly identifying and managing it to improve patient outcomes. The risk of sternal wound infection, the need for tracheostomy, hepatic failure, and paraplegia appeared comparable between the two groups. However, this observation may be attributed to the limited number of studies reporting these outcomes, resulting in insufficient power to draw definitive conclusions.

Our study revealed a nearly four-fold increase in the 30-day mortality risk among patients with AKI (18.36% compared to 4.75%). These findings align with those of Ko *et al.*, who reported a higher 30-day mortality rate in their AKI group. Notably, they reported that the

severity of AKI was a significant predictor of mortality. Specifically, AKI stage 3, the most severe stage, was identified as an independent risk factor for mortality with a hazard ratio of 6.83, even after adjusting for potential confounding factors. Additionally, extracorporeal circulation time, BMI, elevated perioperative peak serum C-reactive protein concentration, reduced renal perfusion, and perioperative sepsis have been identified as risk factors for AKI development [37]. Furthermore, a study by Li *et al.* revealed a significantly higher overall postoperative in-hospital mortality rate in the AKI group than that in the non-AKI group (21.2% vs. 9.6%). The mortality rate increased with each stage of AKI, with stage 3 exhibiting the highest mortality rate (70.59%) [38].

AKI has been associated with a complex and challenging postoperative course in numerous studies [4,13,14,23,41,42,44]. Our meta-analysis builds on this existing knowledge by comprehensively examining the intricate relationship between AKI and postoperative complications following TAAD repair. Our findings demonstrate a significant association between AKI and a multitude of adverse events. Patients with AKI exhibited a nearly threefold increased risk of cardiovascular complications (P < 0.001), an over two-fold increased risk of sepsis (P < 0.001), and a more than two-fold increased risk of stroke (P < 0.001). Additionally, patients with AKI had a greater than two-fold increased risk of stroke risk of stroke (P < 0.001).

Fig.	. 3
------	-----

(a)	AK	I	Non-	AKI		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Tota	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Arnaoutakis 2023	122	761	180	2546	25.7%	2.27 [1.83, 2.81]	-
Brown 2022	4	85	22	516	3.4%	1.10 [0.39, 3.12]	_
Chen 2023	40	153	28	229	13.3%	2.14 [1.38, 3.31]	
Helgason 2021	168	382	116	559	26.9%	2.12 [1.74, 2.58]	-
Ko 2015	24	165	15	210	8.3%	2.04 [1.10, 3.76]	_
Sansone 2015	2	14	3	23	1.4%	1.10 [0.21, 5.77]	
Sasabuci 2016	18	181	13	222	6.9%	1.70 (0.86, 3.37)	
Wang-1 2020	12	114	8	100	4.8%	1.32 [0.56, 3.09]	
Yang 2022	57	268	6	130	5.2%	4.61 [2.04, 10.41]	
Zhao 2015	20	72	2	36	1.9%	5.00 [1.24, 20.22]	
Zona 2020	3	51	9	70	2.4%	0.46 [0.13, 1.61]	
Total (95% CI)		2246		4641	100.0 %	2.05 [1.68, 2.50]	▲
Total events	470		402				
Heterogeneity: Tau ² =	0.03; Ch	i² = 14	.81, df = 1	0 (P =	0.14); l ² =	32%	
Test for overall effect:	Z = 7.04	(P < 0.	00001)			0.01	Eavours (AKI) Eavours (non-AKI)
(h)							
	AKI	T-4-1	Non-Ar	(T-4-1		Risk Ratio	Risk Ratio
Study or Subgroup	EVents		LUONTO		weight	M-H. Random, 95% CI	
	LVCIRG	Total	Events				M-H, Random, 95% CI
Arnaoutakis 2023	342	761	0	2546	5.8% 2	289.63 [143.09, 36636.23]	<u></u>
Arnaoutakis 2023 Fang 2023	342 100	761 314	0 4	2546 307	5.8% 2 8.3%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58]	м-н, капdom, 95% СГ
Arnaoutakis 2023 Fang 2023 Guan 2023	342 100 38	761 314 88	0 4 0	2546 307 84	5.8% 2 8.3% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13]	
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021	342 100 38 105	761 314 88 382	0 4 0 4	2546 307 84 559	5.8% 2 8.3% 5.8% 8.3%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37]	
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015	342 100 38 105 31	761 314 88 382 165	0 4 0 4 2	2546 307 84 559 210	5.8% 2 8.3% 5.8% 8.3% 7.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23]	
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Oki 2015	342 100 38 105 31 41	761 314 88 382 165 241	0 4 0 4 2 0	2546 307 84 559 210 94	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33]	
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015	342 100 38 105 31 41 10	761 314 88 382 165 241 56	0 4 0 4 2 0 0	2546 307 84 559 210 94 99	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 49 [40 [2.00, 721 76]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sansone 2015	342 100 38 105 31 41 10 14	761 314 88 382 165 241 56 14	0 4 0 4 2 0 0 0	2546 307 84 559 210 94 99 23 232	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 720, 26]	
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sansone 2016 Wang 1 2020	342 100 38 105 31 41 10 14 17 21	761 314 88 382 165 241 56 14 181 114	0 4 0 4 2 0 0 0 0 0	2546 307 84 559 210 94 99 23 222 100	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 417]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020	342 100 38 105 31 41 10 14 17 31 89	761 314 88 382 165 241 56 14 181 114 359	0 4 0 4 2 0 0 0 0 0 12 22	2546 307 84 559 210 99 23 222 100 353	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8% 5.8% 5.8% 8.6% 8.6%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 376 [2.44, 5.81]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020 Xu 2023	342 100 38 105 31 41 10 14 17 31 88 95	761 314 88 382 165 241 56 14 181 114 359 235	0 4 0 4 2 0 0 0 0 12 23 0	2546 307 84 559 210 94 99 23 222 100 353 389	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8% 5.8% 8.6% 8.6% 8.6%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 3.76 [2.44, 5.81] 315 64 [19.69, 5059.07]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020 Xu 2023 Yang 2022	342 100 38 105 31 41 10 14 17 31 88 95 57	761 314 88 382 165 241 56 14 181 114 359 235 268	0 4 0 4 2 0 0 0 0 0 12 23 0 0	2546 307 84 559 210 94 99 23 222 100 353 389 130	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8% 5.8% 8.6% 8.6% 8.7% 5.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 3.76 [2.44, 5.81] 315.64 [19.69, 5059.07] 56 00 [3.49, 899.11]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020 Xu 2023 Yang 2022 Zhao 2015	342 100 38 105 31 41 10 14 17 31 88 95 57 15	761 314 88 382 165 241 56 14 181 114 359 235 268 72	0 4 0 4 2 0 0 0 0 0 12 23 0 0 0 0 0	2546 307 84 559 210 94 99 23 222 100 353 389 130 36	5.8% 2 8.3% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 8.6% 8.7% 5.8% 5.8% 5.8% 5.8%	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 3.76 [2.44, 5.81] 315.64 [19.69, 5059.07] 56.00 [3.49, 899.11] 15 71 [0.97, 255 36]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020 Xu 2023 Yang 2022 Zhao 2015 Zono 2020	342 100 38 105 31 41 10 14 17 31 88 95 57 15	761 314 88 382 165 241 56 14 181 114 359 235 268 72 51	0 4 0 4 2 0 0 0 0 0 12 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2546 307 84 559 210 94 99 23 222 100 353 389 130 36 70	5.8% 2 8.3% 5.8% 8.3% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 3.76 [2.44, 5.81] 315.64 [19.69, 5059.07] 56.00 [3.49, 899.11] 15.71 [0.97, 255.36] 42.33 [2.59, 691.43]	M-H, Kandom, 95% CI
Arnaoutakis 2023 Fang 2023 Guan 2023 Helgason 2021 Ko 2015 Li 2020 Qiu 2015 Sansone 2015 Sasabuci 2016 Wang-1 2020 Wang-2 2020 Xu 2023 Yang 2022 Zhao 2015 Zong 2020	342 100 38 105 31 41 10 14 17 31 88 95 57 15 15	761 314 88 382 165 241 56 14 181 114 359 235 268 72 51	0 4 0 4 2 0 0 0 0 0 12 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2546 307 84 559 210 94 99 23 222 100 353 389 130 36 70	5.8% 2 8.3% 5.8% 8.3% 7.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5	289.63 [143.09, 36636.23] 24.44 [9.11, 65.58] 73.54 [4.59, 1178.13] 38.41 [14.27, 103.37] 19.73 [4.79, 81.23] 32.58 [2.02, 524.33] 36.84 [2.20, 617.06] 46.40 [2.98, 721.76] 42.88 [2.60, 708.26] 2.27 [1.23, 4.17] 3.76 [2.44, 5.81] 315.64 [19.69, 5059.07] 56.00 [3.49, 899.11] 15.71 [0.97, 255.36] 42.33 [2.59, 691.43]	M-H, Kandom, 95% CI

Heterogeneity: Tau² = 3.92; Chi² = 143.91, df = 14 (P < 0.00001); l² = 90% Test for overall effect: Z = 5.94 (P < 0.00001)

Total events

999

45

0.1 1 10 200 Favours (AKI) Favours (non-AKI)

Forest plots for the outcome of (a) stroke and (b) the need for dialysis/CRRT. CRRT, continuous renal replacement therapy.

re-exploration for bleeding (P < 0.001), experienced prolonged hospital stay, and required extended ICU stay. However, there was no significant difference between the two groups in terms of sternal wound infection, need for tracheostomy, paraplegia, and hepatic failure.

Early initiation of RRT has been suggested as a means of improving patient outcomes [14]. However, findings from the study by Wang *et al.* challenged this notion, indicating that even with timely postoperative RRT, patients still experience elevated rates of perioperative mortality and postoperative morbidity [13]. Our findings align with these observations, demonstrating a significantly higher prevalence of dialysis/CRRT in the AKI group than in the non-AKI group (30.2% vs. 0.8%). Moreover, the RRT procedure itself carries potential complications, including circulatory instability, infection, thrombosis, and electrolyte imbalance, which could negatively affect patient recovery and prognosis [45].

0.005

Recent advances have shed light on the complex mechanisms that underlie AKI. The pathophysiology of AKI involves a cascade of events, including hemodynamic imbalances, inflammatory responses, immune system dysfunction, dysregulation of iron metabolism, increased oxidative stress, and associated inflammation [7]. Since there is currently no specific treatment for postoperative AKI in TAAD patients, preventive measures such as careful management of blood pressure and anemia during repair, utilizing new technologies to shorten the time organs are deprived of blood flow, and avoiding exposure to nephrotoxic substances may be crucial for protecting

Fig.	4
------	---

(a) AKI	Non-AK	(Tatal Waisht	Risk Ratio	Risk Ratio
Study of Subgroup Events Tota	ii Events	Total weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Arnaoutakis 2023 97 76	1 93.	2546 17.7%	3.49 [2.66, 4.58]	
Chen 2023 9 15	3 4	229 10.1%	3.37 [1.06, 10.74]	
Heigason 2021 316 38	2 314	559 18.4%	1.47 [1.35, 1.61]	-
K0 2015 3 16	5 U	210 2.9%	8.90 [0.46, 171.05]	
Liu y 2020 2 8	2 0	48 2.8%	2.95 [0.14, 60.23]	
Qiu 2015 8 5	62	99 7.6%	7.07 [1.56, 32.15]	
Sasabuci 2016 6 18	16	222 10.4%	1.23 [0.40, 3.74]	
Wang-1 2020 6 11	4 2	100 7.3%	2.63 [0.54, 12.75]	
Xu 2023 8 23	55	389 10.5%	2.65 [0.88, 8.00]	
Yang 2022 51 28	85	130 12.4%	4.95 [2.02, 12.10]	
Total (95% CI) 239	7	4532 100.0%	2.85 [1.65, 4.92]	◆
Total events 506	431			
Heterogeneity: Tau ² = 0.42; Chi ² = 6	1.89, df = 9 (P < 0.00001); I	²= 85%	
Test for overall effect: Z = 3.77 (P = 1	1.0002)			U.U1 U.1 1 1U 100 Favours (AKI) Favours (non-AKI)
(b) AKI	Non-AK	(1	Risk Ratio	Risk Ratio
Study or Subgroup Events Tota	al Events	Total Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Helgason 2021 176 38	2 76	559 20.4%	3.39 [2.68, 4.29]	· · · · · · · · · · · · · · · · · · ·
Li 2020 31 24	1 16	94 18.0%	0.76 [0.43, 1.32]	
Liu 2021 18 6	1 2	54 9.9%	7.97 [1.94, 32.77]	·
Liu Y 2020 44 8	28	48 16.9%	3.22 [1.66, 6.25]	
Qiu 2015 12 5	6 18	99 17.0%	1.18 [0.61, 2.26]	_
Sansone 2015 7 1	46	23 14.8%	1.92 [0.81, 4.55]	
Wang-1 2020 1 11	4 0	100 3.1%	2.63 [0.11, 63.96]	
Yang 2022 268 4	2 130	18	Not estimable	
Total (95% CI) 99	2	995 100.0%	2.13 [1.16, 3.91]	•
Total events 557	256		• • •	
Heterogeneity: Tau ² = 0.46; Chi ² = 3	292 df = 6 (P < 0.0001) [,] P	= 82%	
Test for overall effect: Z = 2.43 (P = 1	1.02)		02,0	0.01 0.1 1 10 100 Favours (AKI) Favours (non-AKI)
(c) AKI	Non-AK	(1	Risk Ratio	Risk Ratio
Study or Subgroup Events Tota	I Events	Total Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Brown 2022 11 8	5 7	516 20.0%	9.54 [3.80, 23.92]	
Guan 2023 28 8	82	84 12.8%	13.36 [3.29, 54.36]	
Helgason 2021 65 38	2 37	559 31.0%	2.57 [1.75, 3.77]	
Ko 2015 29 16	59	210 24.0%	4.10 [2.00, 8.42]	_ _
Yang 2022 18 26	82	130 12.3%	4.37 [1.03, 18.53]	
Total (95% CI) 98	8 .	1499 100.0%	4.92 [2.62, 9.24]	
Total events 151	57			
Heterogeneity: Tau ² = 0.29: Chi ² = 1	0.97.df=4.0	P = 0.03); $P = 0.03$	ì4%	
Test for overall effect: Z = 4.97 (P < 1	0.00001)			0.01 0.1 1 10 100 Favours (AKI) Favours (non-AKI)

Forest plots for the outcomes of (a) cardiovascular complications, (b) respiratory complications, and (c) sepsis.

kidney function [46]. The early diagnosis of AKI can lead to timely treatment and improved outcomes [47]. Currently, AKI is diagnosed on the basis of serum creatinine levels, glomerular filtration rate, and urine output. However, these tests are not always accurate early in the course of AKI and cannot predict the outcomes. Recently, researchers have looked at biomarkers for the early diagnosis of AKI. Two promising biomarkers are neutrophil gelatinase-associated lipocalin and cystatin C [38,48–50]. While these studies focused on cardiac procedures, they did not investigate the diagnostic effectiveness of these biomarkers in TAAD patients. Further research is warranted to validate the utility of these biomarkers for TAAD diagnosis.

Overall, this meta-analysis provides valuable insights into the association between AKI and adverse outcomes after TAAD repair. Further clinical trials are necessary to determine preventive strategies and reduce the burden of AKI in this patient population.

Fig		5
-----	--	---

(a)	AKI		Non-A	KI		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Arnaoutakis 2023	100	761	123	2546	18.7%	2.72 [2.12, 3.50]	+
Brown 2022	18	85	36	516	13.6%	3.04 [1.81, 5.09]	
Chen 2023	13	153	5	229	6.8%	3.89 [1.42, 10.69]	
Guan 2023	14	88	2	84	4.0%	6.68 [1.57, 28.52]	
Helgason 2021	108	382	85	559	18.6%	1.86 [1.44, 2.39]	-
Liu 2021	8	61	1	54	2.2%	7.08 [0.92, 54.81]	
Sansone 2015	5	14	1	23	2.2%	8.21 [1.07, 63.28]	
Sasabuci 2016	17	181	5	222	7.1%	4.17 [1.57, 11.08]	
Wang-1 2020	5	114	5	100	5.3%	0.88 [0.26, 2.94]	
Wang-2 2020	13	359	16	353	10.3%	0.80 [0.39, 1.64]	
Xu 2023	20	235	9	389	9.5%	3.68 [1.70, 7.94]	
Zong 2020	1	51	2	70	1.7%	0.69 [0.06, 7.36]	
Total (95% CI)		2484		5145	100.0%	2.46 [1.79, 3.39]	•
Total events	322		290				
Heterogeneity: Tau ² =	0.13: Chi	² = 25.	96. df = 1	1 (P = (0.007): I ² :	= 58%	
Test for overall effect:	Z = 5.50 ((P < 0.0	00001)				0.01 0.1 1 10 100 Eavours [AKI] Eavours [non-AKI]
(1-)							ravous (aug ravous frontaug
(D)	AKI		Non-A	KI		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Helgason 2021	12	382	10	559	59.2%	1.76 [0.77, 4.02]	
Wang-1 2020	2	114	3	100	13.0%	0.58 (0.10, 3.43)	
Wang-2 2020	4	359	5	353	23.8%	0.79 [0.21, 2.91]	_
Zong 2020	0	51	1	70	4.0%	0.46 [0.02, 10.95]	•
Total (95% CI)		906		1082	100.0%	1 10 [0 63 2 25]	
Total (35% Cl)	40	500	40	1002	100.070	1.15 [0.05, 2.25]	
Total events	0.00.06	2 - 2 2	ט אר ביו 19	0-06	21/12 - 00	,	
Telefoyenelly. Tau" =	7 - 0 54 /	- 2.2 D - 0.4	∪,ui= 3 (:0\	F = 0.5	3), 17 = 09	0	'0.01 0.1 i 10 100'
restior overall ellect.	Z = 0.94 ((F = 0.0	19)				Favours [AKI] Favours [non-AKI]
(c)	AKI		Non-A	к		Risk Ratio	Risk Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	M-H. Random, 95% Cl
Helasson 2021	75	382	14	550	23.4%	7 84 (4 50 13 66)	
1/o 2015	, 5	166	2	210	16.6%	5 00 (1 10 22 66)	
No 2013 Wong 1 2020	0 A	114	5	100	10.0%	1 05 (0 22 2 24)	
Wang-1 2020	10	260	15	262	19.370	1.00 [0.00, 0.04]	
Vvarig-2 2020 Zong 2020	19	508	10	303	22.070	1.20 [0.04, 2.41]	
2011g 2020	3	51	0	70	18.0%	0.09 [0.18, 2.02]	-
Total (95% CI)		1071		1292	100.0%	2.10 [0.72, 6.15]	
Total events	111		42				
Heterogeneity: Tau² =	1.21; Chi	z = 26.	93, df = 4	(P < 0.	0001); I²:	= 85%	
Test for overall effect:	Z=1.35 ((P = 0.1	8)				Favours [AKI] Favours [non-AKI]

Forest plots for the outcomes of (a) reexploration for bleeding, (b) sternal wound infection, and (c) the need for tracheostomy.

Limitations

Our study had several limitations. First, the studies included in this review were observational, and while they offer valuable insights, they are inherently susceptible to biases that are not present in randomized controlled trials. Second, although the quality of these studies, as evaluated using the Newcastle-Ottawa Scale, was high, the results varied, which may have affected the outcomes. Third, more than half of the studies included in this analysis focused on the Chinese population, thereby limiting the generalizability of the results to patients from other ethnic backgrounds. Fourth, significant heterogeneity was observed across the studies owing to differences in study design, patient characteristics, repair techniques, and definitions of outcomes. Although the sensitivity analysis attempted to address some of the heterogeneity, it remained high for certain outcomes, indicating that the results should be interpreted with caution. Fifth, in the process of conducting an extensive literature search, there may still be a risk of publication bias as studies with negative findings are often less published. This could potentially skew the findings of this study. Sixth, for

Fig. 6

(a) Study or Subgroup	AKI Na Events Total Eve			Non-AKI vents Total		Risk Ratio Weight M-H. Random, 95% Cl		Risk Ratio M-H. Random, 95% Cl	
Wang-1 2020	2	114	3	100	15.7%)	0.58 (0.10, 3.43)		
Wang-2 2020	11	359	13	353	78.7%	r n	0.83 [0.38, 1.83]	_ 	
Zong 2020	0	51	3	70	5.7%	,)	0.20 [0.01, 3.70]		
	-		-						
Total (95% CI)		524		523	100.0%	, ,	0.73 [0.36, 1.46]	-	
Total events	13		19						
Heterogeneity: Tau² = 0.00; Chi² = 0.95, df = 2 (P = 0.62); l² = 0%									
Test for overall effect	: Z = 0.90	(P = 0.3	37)					Favours [AKI] Favours [non-AKI]	
(b)	АК	1	Non-	1KI		F	Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	м.н.	Random, 95% Cl	M-H. Bandom, 95% Cl	
Li 2020	24	241	17	0.0 Q.4	52.0%		0.55.00.21.0.0.91		
Vana 2022	24	241		120	12.07	, . ,		-	
1 ang 2022	54	200	4	150	40.0 Å	, ,	.12[1.45, 11.57]		
Total (95% CI)		509		224	100.0%	5 1	.45 [0.18, 11.55]		
Total events	58		21						
Heterogeneity: Tau ² :	= 2.07; Ch	i ² = 12.	73, df = 1	(P = 0.	0004); P	²= 92%			
Test for overall effect	: Z = 0.35	(P = 0.7	73)					U.U1 U.1 1 10 100 Eavours [AKI] Eavours [non-AKI]	
(\mathbf{c})	-								
(C) Study or Subgroup	A	KI SD TA	tal Moa	Non-AK	l Total	Moight	Mean Difference	Mean Difference	
Brown 2022	21.0	30 IU 24 7	05 10	7 00	516	10.0%	11 20 16 51 15 0		
Guan 2022	15.65	21.7 5.78	00 10 99 1 <i>1</i>	7 7 5.0	94	10.0%	0.05 [0.01, 10.03	oj – –	
Li 2020	22.86 11	0.20 1.23 ()	741 717	1 8 9 8	94	17.9%	1 15 [-1 08 3 3	81	
Sansone 2015	17.3	16.8	14 13	3 8.4	23	4.2%	4.00 [-5.45, 13.4]	51	
Wang-2 2020	24.5	14.6 3	359 20	1 9.7	353	19.1%	4.40 [2.58, 6.2]	21	
Zhang 2022	17	9.9	53 15	3 6.7	171	16.0%	1.70 [-1.15, 4.5	si +	
Zong 2020	24.7	12.2	51 19	7 7.5	70	13.2%	5.00 [1.22, 8.7)	8] ——	
Total (05% CI)			004		4244	100.0%	2 54 14 20 5 70		
Hotorogonoity: Tou2 -	5 40· Chiz	- 22.76	991 df = 6 /0	- 0.000	0):12 - 7	100.0%	5.54 [1.56, 5.70		
Test for overall effect:	5.46, Chi 7 = 3.21 (P	- 22.70	, ui – 0 (r I)	- 0.000	9), 1 – 7	4 70		-20 -10 0 10 20	
	2 - 3.21 (1	- 0.001	·/					Favours (AKI) Favours (non-AKI)	
(d)	A	KI		Non-AK	I		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD To	otal Mea	n SD	Total	Weight	IV, Random, 95% (CI IV, Random, 95% CI	
Fang 2023	13.4 13	2.45 3	314 7.6	2 7.74	307	31.1%	5.78 [4.15, 7.41	1]	
Sansone 2015	19 1	18.1	14	6 6.8	23	4.3%	13.00 [3.12, 22.8	8]→	
Wang-2 2020	8	6.4 3	359 5	8 14.1	353	31.2%	2.20 [0.59, 3.8]		
20ng 2020	б. <i>1</i>	4.5	51 3	8 1.5	70	33.3%	2.90 [1.62, 4.1)	8]	
Total (95% Cl)		7	738		753	100.0%	4.01 [1.83, 6.20	D] 🔶	
Heterogeneity: Tau ² = 3.29; Chi ² = 14.41, df = 3 (P = 0.002); l ² = 79%									
Test for overall effect:	Z = 3.60 (P	= 0.000)3)					-20 -10 0 10 20 Favours (AKI) Favours (non-AKI)	

Forest plots for the outcomes of (a) paraplegia, (b) hepatic failure, (c) lengths of stay in hospital, and (d) lengths of stay in ICU.

some outcomes, the data were limited, leading to wider confidence intervals and less precise estimates. This limitation highlights the need for further research to confirm our findings. Finally, most studies had a follow-up duration of at least 30 days, but long-term outcomes were not considered. This could have provided more information about the effects of AKI following TAAD repair, indicating a gap in the current research.

Despite these limitations, this systematic review and meta-analysis provides valuable insights into the outcomes of AKI following TAAD repair. Future research should address these limitations and provide more definitive conclusions.

Conclusion

In conclusion, this meta-analysis confirms that postoperative AKI is significantly associated with adverse outcomes following repair of TAAD, including increased mortality, stroke, dialysis/CRRT requirement, cardiovascular and respiratory complications, sepsis, reexploration for bleeding, and prolonged hospital and ICU stays. Future research should aim to standardize patient populations and outcome definitions to enhance understanding of AKI's prognostic significance in these patients. Additionally, large-scale multicenter studies, including randomized controlled trials, prospective studies, are required to validate these findings and to better understand long-term outcomes in these patients.

Acknowledgements

A.G. contributed to the conceptualization, investigation, data curation, methodology, formal analysis, and writing – original draft. S.M. contributed to the investigation, data curation, and formal analysis. H.Q.A. contributed to the data curation, methodology, and writing – original draft. Y.M. contributed to the investigation, data curation, and writing – original draft. U.S. and M.C. contributed to the methodology and writing – original draft. D.S. and H.J. contributed to the writing – original draft. D.S. and H.J. contributed to the writing – review and editing and supervision. P.P. contributed to the writing – review and editing and supervision. All authors read and approved the final manuscript.

All datasets generated and analyzed are available in the article and supplementary materials.

Conflicts of interest

There are no conflicts of interest.

References

- Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE. Management of acute aortic dissections. *Ann Thorac Surg* 1970; 10:237–247.
- 2 Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, et al. Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from the International Registry of Acute Aortic Dissection. J Am Coll Cardiol 2015; 66:350–358.
- 3 Parikh N, Trimarchi S, Gleason TG, Kamman AV, di Eusanio M, Myrmel T, et al. Changes in operative strategy for patients enrolled in the International Registry of Acute Aortic Dissection interventional cohort program. J Thorac Cardiovasc Surg 2017; 153:S74–S79.
- 4 Sasabuchi Y, Kimura N, Shiotsuka J, Komuro T, Mouri H, Ohnuma T, et al. Long-term survival in patients with acute kidney injury after acute type A aortic dissection repair. Ann Thorac Surg 2016; 102:2003–2009.
- 5 Collins JS, Evangelista A, Nienaber CA, Bossone E, Fang J, Cooper JV, et al. Differences in clinical presentation, management, and outcomes of acute type A aortic dissection in patients with and without previous cardiac surgery. *Circulation* 2004; **110**(11 Suppl 1):II237–II242.
- 6 Zhao H, Pan X, Gong Z, Zheng J, Liu Y, Zhu J, Sun L. Risk factors for acute kidney injury in overweight patients with acute type A aortic dissection: a retrospective study. J Thorac Dis. 2015; 7:1385–1390.
- 7 Nadim MK, Forni LG, Bihorac A, Hobson C, Koyner JL, Shaw A, et al. Cardiac and vascular surgery-associated acute kidney injury: the 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group. J Am Heart Assoc 2018; 7:e008834.
- 8 Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1:19–32.
- 9 Seese L, Sultan I, Gleason TG, Navid F, Wang Y, Thoma F, Kilic A. The impact of major postoperative complications on long-term survival after cardiac surgery. *Ann Thorac Surg* 2020; **110**:128–135.
- 10 Thiele RH, Isbell JM, Rosner MH. AKI associated with cardiac surgery. *Clin J Am Soc Nephrol* 2015; **10**:500–514.
- 11 Wang Z, Ge M, Chen T, Chen C, Zong Q, Lu L, Wang D. Independent risk factors and the long-term outcomes for postoperative continuous renal replacement treatment in patients who underwent emergency surgery for type A acute aortic dissection. J Cardiothorac Surg 2020; 15:100.

- 12 Wang L, Zhong G, Lv X, Dong Y, Hou Y, Dai X, Chen L. Risk factors for acute kidney injury after Stanford type A aortic dissection repair surgery: a systematic review and meta-analysis. *Ren Fail* 2022; 44:1462–1476.
- 13 Wang J, Yu W, Zhai G, Liu N, Sun L, Zhu J. Independent risk factors for postoperative AKI and the impact of the AKI on 30-day postoperative outcomes in patients with type A acute aortic dissection: an updated metaanalysis and meta-regression. J Thorac Dis. 2018; 10:2590–2598.
- 14 Roh GU, Lee JW, Nam SB, Lee J, Choi JR, Shim YH. Incidence and risk factors of acute kidney injury after thoracic aortic surgery for acute dissection. *Ann Thorac Surg* 2012; **94**:766–771.
- 15 Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:c179–c184.
- 16 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004; 8:R204–R212.
- 17 Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11:R31.
- 18 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International Journal of Surgery (2021):88;105906. Ann Intern Med 2015; 162:777–784.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR
 a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017; 358:j4008.
- 20 Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Hospital Research Institute. 2011;2(1):1-2.
- 21 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**:557–560.
- 22 Wang Z, Ge M, Chen T, Chen C, Zong Q, Lu L, et al. Risk factors and longterm outcomes of elderly patients complicating with acute kidney injury after type A acute aortic dissection surgery: a retrospective study. J Thorac Dis. 2020; 12:5833–5841.
- 23 Wang Z, Ge M, Chen T, Chen C, Zong O, Lu L, Wang D. Acute kidney injury in patients operated on for type A acute aortic dissection: incidence, risk factors and short-term outcomes. *Interact Cardiovasc Thorac Surg* 2020; 31:697–703.
- 24 Brown JA, Serna-Gallegos D, Navid F, Thoma FW, Zhu J, Kumar R, et al. The long-term impact of acute renal failure after aortic arch replacement for acute type A aortic dissection. J Card Surg 2022; 37:2378–2385.
- 25 Arnaoutakis GJ, Ogami T, Patel HJ, Pai CŴ, Woznicki EM, Brinster DR, et al. Acute kidney injury in patients undergoing surgery for type A acute aortic dissection. Ann Thorac Surg 2023; 115:879–885.
- 26 Li CN, Ge YP, Liu H, Zhang CH, Zhong YL, Chen SW, et al. Blood transfusion and acute kidney injury after total aortic arch replacement for acute Stanford type A aortic dissection. *Heart Lung Circ* 2022; 31:136–143.
- 27 Chen S, Zhang C, Zhong Y, Tang B, Xie Q, Guo R, et al. Association between preoperative serum myoglobin and acute kidney injury after Stanford type A aortic dissection surgery. *Clin Chim Acta* 2023; 541:117232.
- 28 Fang M, Li J, Fang H, Wu J, Wu Z, He L, *et al.* Prediction of acute kidney injury after total aortic arch replacement with serum cystatin C and urine N-acetyl-β-d-glucosaminidase: a prospective observational study. *Clin Chim Acta* 2023; **539**:105–113.
- 29 Guan XL, Li L, Jiang WJ, Gong M, Li HY, Liu YY, *et al.* Low preoperative serum fibrinogen level is associated with postoperative acute kidney injury in patients with in acute aortic dissection. *J Cardiothorac Surg* 2023; 18:6.
- 30 Liu T, Fu Y, Liu J, Liu Y, Zhu J, Sun L, et al. Body mass index is an independent predictor of acute kidney injury after urgent aortic arch surgery for acute DeBakey Type I aortic dissection. J Cardiothorac Surg 2021; 16:145.
- 31 Liu Y, Shang Y, Long D, Yu Li. Intraoperative blood transfusion volume is an independent risk factor for postoperative acute kidney injury in type A acute aortic dissection. BMC Cardiovasc Disord 2020; 20:446.
- 32 Qiu Z, Chen L, Cao H, Zhang G, Xu F, Chen Q. Analysis of risk factors for acute kidney injury after ascending aortic replacement combined with open placement of triple-branched stent graft in type A aortic dissection: a new technique versus the traditional method in a single Chinese center. *Med Sci Monit* 2015; 21:674–680.

- 33 Xu S, Wu Z, Liu Y, Zhu J, Gong M, Sun L, *et al.* Influence of preoperative serum albumin on acute kidney injury after aortic surgery for acute type A aortic dissection: a retrospective cohort study. *J Clin Med* 2023; 12:1581.
- 34 Zhang K, Shang J, Chen Y, Huo Y, Li B, Hu Z. The prognosis and risk factors for acute kidney injury in high-risk patients after surgery for type A aortic dissection in the ICU. *J Thorac Dis.* 2021; **13**:4427–4437.
- 35 Zhang Y, Lan Y, Chen T, Chen Q, Guo Z, Jiang N. Prediction of acute kidney injury for acute type A aortic dissection patients who underwent sun's procedure by a perioperative nomogram. *Cardiorenal Med* 2022; 12:117–130.
- 36 Kim WH, Lee JH, Kim E, Kim G, Kim HJ, Lim HW. Can we really predict postoperative acute kidney injury after aortic surgery? Diagnostic accuracy of risk scores using gray zone approach. *Thorac Cardiovasc Surg* 2016; 64:281–289.
- 37 Ko T, Higashitani M, Sato A, Uemura Y, Norimatsu T, Mahara K, *et al.* Impact of acute kidney injury on early to long-term outcomes in patients who underwent surgery for type A acute aortic dissection. *Am J Cardiol* 2015; 116:463–468.
- 38 Li L, Zhou J, Hao X, Zhang W, Yu D, Xie Y, et al. The incidence, risk factors and in-hospital mortality of acute kidney injury in patients after surgery for acute type A aortic dissection: a single-center retrospective analysis of 335 patients. Front Med (Lausanne) 2020; 7:557044.
- 39 Yang C, Hou P, Wang D, Wang Z, Duan W, Liu J, et al. Serum myoglobin is associated with postoperative acute kidney injury in Stanford type A aortic dissection. Front Med (Lausanne) 2022; 9:821418.
- 40 Zong Q, Ge M, Chen T, Chen C, Wang Z, Wang D. Risk factors and longterm outcomes of acute kidney injury complication after type A acute aortic dissection surgery in young patients. J Cardiothorac Surg 2020; 15:315.
- 41 Helgason D, Helgadottir S, Ahlsson A, Gunn J, Hjortdal V, Hansson EC, et al. Acute kidney injury after acute repair of type A aortic dissection. Ann Thorac Surg 2021; 111:1292–1298.

- 42 Sansone F, Morgante A, Ceresa F, Salamone G, Patanè F. Prognostic implications of acute renal failure after surgery for type A acute aortic dissection. *Aorta (Stamford)* 2015; 3:91–97.
- 43 Mori Y, Sato N, Kobayashi Y, Ochiai R. Acute kidney injury during aortic arch surgery under deep hypothermic circulatory arrest. J Anesth 2011; 25:799–804.
- 44 Tsai HS, Tsai FC, Chen YC, Wu L-S, Chen S-W, Chu J-J, et al. Impact of acute kidney injury on one-year survival after surgery for aortic dissection. Ann Thorac Surg 2012; 94:1407–1412.
- 45 Hanafusa N, Nakai S, Iseki K, Tsubakihara Y. Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population. *Kidney Int Suppl (2011)* 2015; 5:15–22.
- 46 Ostermann M, Cennamo A, Meersch M, Kunst G. A narrative review of the impact of surgery and anaesthesia on acute kidney injury. *Anaesthesia* 2020; 75:121–133.
- 47 Hoogmoed RC, Patel HJ, Kim KM, Williams DM, Deeb GM, Yang B. Acute kidney injury in acute type B aortic dissection: outcomes over 20 years. *Ann Thorac Surg* 2019; **107**:486–492.
- 48 KDIGO (Kidney Disease: Improving Global Outcomes) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Inter Suppl* 2012; 2:1–138.
- 49 Nishigawa K, Fukui T, Uemura K, Takanashi S, Shimokawa T. Preoperative renal malperfusion is an independent predictor for acute kidney injury and operative death but not associated with late mortality after surgery for acute type A aortic dissection. *Eur J Cardiothorac Surg* 2020; 58:302–308.
- 50 Qin H, Li Y, Zhang N, Wang T, Fan Z. Prediction efficiency of postoperative acute kidney injury in acute Stanford type A aortic dissection patients with renal resistive index and semiquantitative color doppler. *Cardiol Res Pract* 2019; **2019**:4381052.